Application Research of FAPI PET/MRI, 18F-Fluorodeoxyglucose (FDG) PET/MRI, and MRI in Diagnosing Muscle-Invasive Bladder Cancer and Evaluating Neoadjuvant Therapy Efficacy

What this Trial Is About

Researchers are evaluating the use of FAPI PET/MRI, FDG PET/MRI, and MRI imaging techniques to diagnose muscle-invasive bladder cancer (MIBC) and predict how well patients respond to neoadjuvant therapy. The study aims to help doctors adjust treatment plans in a timely manner to benefit patients with MIBC. This prospective trial collects imaging data alongside clinical laboratory and pathological results to compare the accuracy of these imaging methods using postoperative pathology as the standard. Participants with suspected MIBC undergo FAPI PET/MRI, FDG PET/MRI, and MRI scans to assess diagnosis accuracy. Patients confirmed with MIBC then receive these imaging exams both before and after neoadjuvant therapy. Following therapy, patients have either transurethral tumor resection or radical cystectomy based on treatment response and condition. The study compares imaging and clinical data to evaluate how well these methods assess therapy effectiveness and guide treatment decisions. During the study, participants will have imaging exams, clinical laboratory tests, and pathological assessments. Researchers monitor diagnostic accuracy measures such as sensitivity, specificity, and predictive values within one week after surgical pathology results. They also evaluate therapy response outcomes like remission and metabolic response within one month. Long-term outcomes including overall survival and progression-free survival are followed for one to three years. The study runs until June 2029, and all data will help improve diagnosis and treatment monitoring for MIBC patients.

FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer